However, Cecchin et al [39] reported no association between the XPD Lys751Gln allelic variant and the tumor regression grade in 238 rectal cancer patients treated with neoadjuvant chemoradiotherapy in Italy. This evidence concerns the gene ERCC2 and neoplasm.